posted on 2024-04-16, 17:35authored byMartha M. O’Kennedy, Robyn Roth, Karen Ebersohn, Lissinda H. du Plessis, Sipho Mamputha, Daria A. Rutkowska, Ilse du Preez, Jan A. Verschoor, Yolandy Lemmer
Cytotoxicity studies in Vero cells validating the (A) adjuvanted commercial vaccine, (B) VP2 proteins nonavalent (serotypes 1–9) combined versus plant extract, (C) plant produced VP2 proteins nonavalent (serotypes 1–9) combined and adjuvanted with Montanide Gel 01 or (D) plant produced VP2 proteins nonavalent (serotypes 1–9) combined and adjuvanted with Nanoalum. Statistical difference at P < 0.05 (indicated with a *) were considered significant in a two tailed Student’s t test.